MYC and neoplasm: Studies have found that FBXO32 degrades c-Myc through ubiquitination, inhibiting its mediated glycolysis and glutamine metabolism, thereby reducing lactic acid accumulation in the tumor microenvironment and improving the functional failure of CD8 +T cells (67).